Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy license
June 13, 2019 at 21:08 PM EDT
Errant Gene Therapeutics claims in a new lawsuit that local venture capital firm Third Rock Ventures and bluebird bio CEO Nick Leschly worked to hinder its drug development efforts so it could obtain a key part of its intellectual property.
